Letters
Puberty blockers
Legal clarity allows the use of GnRH analogues in research
BMJ 2024; 386 doi: https://doi.org/10.1136/bmj.q1961 (Published 10 September 2024) Cite this as: BMJ 2024;386:q1961
- Susan Bewley, emeritus professor of obstetrics and women’s health1,
- Kath Checkland, professor of health policy and primary care2,
- Paul Garner, emeritus professor in evidence synthesis3,
- Riittakerttu Kaltiala, professor of adolescent psychiatry, chief psychiatrist45,
- Margaret McCartney, senior lecturer6,
- Carl Heneghan, professor of evidence based medicine7,
- Hannah Ryan, clinical pharmacology specialty registrar8
- 1King’s College London, London, UK
- 2University of Manchester, Manchester, UK
- 3Liverpool School of Tropical Medicine, Liverpool, UK
- 4Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- 5Department of Adolescent Psychiatry, Tampere University Hospital, Tampere University, Tampere, Finland
- 6School of Medicine, University of St Andrews, St Andrews, UK
- 7University of Oxford, Oxford, UK
- 8Royal Liverpool University Hospital, Liverpool, UK
- susan.bewley{at}kcl.ac.uk
The Cass review of the care of children and adolescents with gender dysphoria was a wake up call.1 Having commissioned several peer reviewed, systematic reviews of evidence, paediatrician Hilary Cass’s team drew on four years’ comprehensive engagement with service users, parents, clinicians, researchers, and advocacy groups, finding that most children’s gender dysphoria in historical cohorts resolves through puberty; suicidality is equivalent to children with diagnosed mental health …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.